Our products
AASLD San Francisco
17 Nov 2015

Gamal Esmat, MD, professor of Hepatology and endemic medicine at Cairo University and WHO viral Hepatitis expert, presented advanced results of the abstract entitled: high virologic response rate in Egyptian HCV-genotype 4 patients treated with Ravidasvir (PPI-668) and Sofosbuvir: results of a large multicenter phase 3 registrational trial.

Dr. Gamal Esmat, representing Pharco, was the first Arab to present at the closing ceremony, where the major treatment protocols for the upcoming years are agreed upon.